托维妥单抗

托维妥单抗（INN：Tovetumab）是一种抗PDGFRA 单克隆抗体，设计用于治疗癌症。^[1]它由MedImmune开发，并试验用于胶质母细胞瘤和非小细胞肺癌。^[2]对于该药物的开发于2013年停止。^[3]^[4]

存卡里

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. The AAPS Journal. November 2020, 23 (1): 4. PMID 33210183. S2CID 227067803. doi:10.1208/s12248-020-00523-3 .
^ Tovetumab. AdisInsight. Springer Nature Switzerland AG. [2024-03-01]. （原始内容存档于2017-11-03）.
^ Williams R. Discontinued in 2013: oncology drugs. Expert Opinion on Investigational Drugs. January 2015, 24 (1): 95–110. PMID 25315907. S2CID 23390614. doi:10.1517/13543784.2015.971154.